The imperative of influenza vaccines for elderly individuals - An evolving story

Journal of Infectious Diseases

Volumn 200, Issue 2, 2009, Pages 161-163

  Poland, A ^a,b   Mulligan, Mark J ^c  

^a Department of Internal Medicine ^*

^b MAYO CLINIC   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; HEMAGGLUTININ; INFLUENZA VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OSELTAMIVIR; SUBUNIT VACCINE;

ARM SWELLING; CLINICAL TRIAL; COST OF ILLNESS; DRUG MEGADOSE; HEADACHE; HIGH RISK POPULATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INJECTION PAIN; MALAISE; MYALGIA; NOTE; PRIORITY JOURNAL; UNITED STATES;

AGE DISTRIBUTION; AGED; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, INACTIVATED;

EID: 67650660985     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599791     Document Type: Note

References (24)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
2. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza antiviral resistance: a plea for rational use. Clin Infect Dis 2009;48:1254-6.
3. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96.
4. Vu T, Farish S, Jenkins M, Kelly H. A metaanalysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-6.
5. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knotrnerus JA. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994;272:1661-5.
6. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24: 1159-69.
7. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7.
8. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656-63.
9. Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS. Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation. Postgrad Med J 1973;49:152-8.
10. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673-80.
11. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650-8.
12. Treanor J, Dumyati G, O'Brien D, et al. Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. J Infect Dis 1994; 169:402-7.
13. Ohmit SE, Victor JC, Teich ER, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008; 198:312-7.
14. Gorse GJ, O'Connor TZ, Newman FK, et al. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 2004; 190:11-9.
15. Gorse GJ, O'Connor TZ, Young SL, et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003; 21: 2133-44.
16. Treanor JJ, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117:625-33.
17. Targonski PV, Poland GA. Intranasal coldadapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly? Drugs Aging 2004;21:349-59.
18. Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000; 19:308-18.
19. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007;26:119-27.
20. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007; 211: 144-56.
21. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001;75:12182-7.
22. Falsey A, Treanor JJ, Tornieporth N, Capellán J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of highdose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172-80 (in this issue).
23. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 2007;82:653-64.
24. Centers for Disease Control and Prevention. State-specific influenza vaccination coverage among adults-United States, 2006-07 influenza season. MMWR Morb Mortal WkIy Rep 2008;57:1033-9.